Retinal thickness fluctuations in patients receiving fluocinolone acetonide implant for diabetic macular edema

References

• Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XVII. The 14 year incidence and progression of diabetic retinopathy and associated risk factors in type I diabetes. Ophthalmology. 1998;105(10):1801–1815.
   PubMed Web of Science ®Google Scholar
• Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–2022.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. Two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351–1359.
   PubMed Web of Science ®Google Scholar
• Elman MJ, Ayala A, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt vs. deferred laser treatment: 5-year randomized trial results. Ophthalmology. 2015;122(2):375–381.
   PubMed Web of Science ®Google Scholar
• The Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193–1203.
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796–1806.
   PubMed Web of Science ®Google Scholar
• Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–625.
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115:1447–1450.
   PubMed Web of Science ®Google Scholar
• Maturi RK, Pollack A, Uy HS, et al. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year mead study. Retina. 2016;36(6):1143–1152.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–2132.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626–635.
   PubMed Web of Science ®Google Scholar
• Holden SE, Currie CJ, Owens DR. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema. Curr Med Res Opin. 2017;33(2):5–17.
   PubMedGoogle Scholar
• Currie CJ, Holden SE, Berni E, et al. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. Curr Med Res Opin. 2017;33(2):19–31.
   PubMedGoogle Scholar
• El-Ghrably I, Steel DHW, Habib M, et al. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience. Eur J Ophthalmol. 2017;27(3):357–362.
   PubMed Web of Science ®Google Scholar
• Fusi-Rubiano W, Mukherjee C, Lane M, et al. Treating diabetic macular oedema (DME): real world UK clinical outcomes for the 0.19mg fluocinolone acetonide intravitreal implant (IluvienTM) at 2 years. BMC Ophthalmol. 2018;18(1):62.
   PubMedGoogle Scholar
• Currie CJ, Holden SE, Owens DR. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema. Curr Med Res Opin. 2017;33(2):33–43.
   PubMedGoogle Scholar
• Figueira J, Henriques J, Amaro M, et al. A nonrandomized, open-label, multicenter, phase 4 pilot study on the effect and safety of ILUVIEN® in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND). Ophthalmic Res. 2017;57(3):166–172.
   PubMed Web of Science ®Google Scholar
• Schmit-Eilenberger VK. A novel intravitreal fluocinolone acetonide implant (Iluvien(®)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series. Clin Ophthalmol. 2015;9:801–811.
   PubMed Web of Science ®Google Scholar
• Elaraoud I, Andreatta W, Kidess A, et al. Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting. BMC Ophthalmol. 2016;16(1):3.
   PubMedGoogle Scholar
• Elaraoud I, Attawan A, Quhill F. Case series investigating the efficacy and safety of bilateral fluocinolone acetonide (ILUVIEN®) in patients with diabetic macular edema. Ophthalmol Ther. 2016;5(1):95–104.
   PubMed Web of Science ®Google Scholar
• Massin P, Erginay A, Dupas B, et al. Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study. Clin Ophthalmol. 2016;10:1257–1264.
   PubMed Web of Science ®Google Scholar
• Eaton A, Koh SS, Jimenez J, et al. The USER Study: a chart review of patients receiving a 0.2 µg/day fluocinolone acetonide implant for diabetic macular edema. Ophthalmol Ther. 2019;8(1):51–62.
   PubMed Web of Science ®Google Scholar
• Bailey C, Chakravarthy U, Lotery A, et al. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye. 2017;31(12):1707–1715.
   PubMed Web of Science ®Google Scholar
• Holden SE, Currie CJ, Owens DR. Health-economic evaluation of fluocinolone acetonide 190 µg implant in people with diabetic macular edema. Curr Med Res Opin. 2017;33(2):45–52.
   PubMedGoogle Scholar
• Schechet SA, Adams OE, Eichenbaum DA, et al. Macular thickness amplitude changes when switching from discontinuous to continuous therapy for diabetic macular oedema. BMJ Open Ophth. 2019;4(1):e000271.
   PubMed Web of Science ®Google Scholar
• Chin-Yee D, Eck T, Fowler S, et al. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol. 2016;100(7):914–917.
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. The relationship between OCT-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology. 2007;114:525–536.
   PubMed Web of Science ®Google Scholar
• Blumenkranz MS, Haller JA, Kupperman BD, et al. Correlation of visual acuity and macular thickness measured by optical coherence tomography in patients with persistent macular edema. Retina. 2010;30:1090–1094.
   PubMed Web of Science ®Google Scholar